Ornithine decarboxylase inhibitors increase the cellular content of the enzyme: implications for translational regulation.
Ehrlich ascites tumor cells grown in the presence of inhibitors of ornithine decarboxylase (EC 4.1.1.17) exhibited an elevated content of this enzyme. The increase could not solely be explained by a decrease in the degradation rate of the enzyme. Instead a stimulation of enzyme synthesis, probably mediated via the polyamine-depleting properties of the inhibitors, is suggested. The enhancement of cellular ornithine decarboxylase content was not accompanied by any significant changes in the amount of ornithine decarboxylase mRNA, indicating a regulation at the level of translation.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology*; D002460:Cell Line; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA; D000518:Eflornithine; D006207:Half-Life; D009693:Nucleic Acid Hybridization; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D009955:Ornithine Decarboxylase / Q000096:biosynthesis / Q000235:genetics; D065108:Ornithine Decarboxylase Inhibitors; D014176:Protein Biosynthesis / Q000187:drug effects*; D012333:RNA, Messenger / Q000378:metabolism
D065108:Ornithine Decarboxylase Inhibitors; D012333:RNA, Messenger; C025025:alpha-methylornithine; D004247:DNA; D003513:Cycloheximide; D009952:Ornithine; D009955:Ornithine Decarboxylase; D000518:Eflornithine